CMHC.SW COSMO N NV
- Market cap
- CHF 980M
- P/E
- -
- P/B
- 1.82x
- ROE
- -3.3%
- Dividend yield
- 3.38%
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CMHC.SW undervalued?
Graham numberThe Graham number of COSMO N NV cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
COSMO N NV fundamental analysis
7 of 21 checks passedROE 0/2
Low return on equity (-3.3%), below 10%.
ROA 0/1
Return on assets (-2.7%) is below the industry median (7.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-102.8%) is below the industry median (87.9%).
Revenue Growth 1/2
Revenue grew 0.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (0.8%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 2/2
Cash covers 5.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (1.8x) is above the industry median (1.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield cannot be calculated.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
COSMO N NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About COSMO N NV
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to…
Full company profileCOSMO N NV financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
COSMO N NV annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 67.7M | 67.2M | 65.6M | 62.5M | 60.9M | 65.1M | 102M | 92.8M | 267M | 105M | 201M |
| Gross Profit | 57.5M | 55.1M | 53.2M | 53.2M | 50.5M | 49.9M | 83.3M | 53.4M | 247M | 48.8M | 89.2M |
| Operating Income | 21.0M | -15.5M | -16.6M | -12.3M | 6.91M | 11.1M | 28.1M | 6.15M | 149M | -10.5M | -37.7M |
| EBITDA | 28.4M | -28.8M | -12.3M | -7.02M | 7.84M | 18.5M | 47.5M | 18.0M | 166M | 2.27M | -11.3M |
| Net Income | 19.3M | -32.4M | -18.1M | -24.5M | -7.90M | 21.7M | 17.2M | -4.93M | 133M | -3.63M | -19.0M |
| EPS | 1.34 | -2.19 | -1.20 | -1.67 | -0.55 | 1.28 | 1.05 | -0.31 | 8.12 | -0.23 | -1.11 |
| Balance Sheet | |||||||||||
| Total Assets | 443M | 498M | 626M | 585M | 596M | 806M | 760M | 554M | 647M | 612M | 696M |
| Total Liabilities | 27.9M | 27.9M | 181M | 191M | 196M | 293M | 296M | 125M | 142M | 123M | 122M |
| Shareholders' Equity | 416M | 470M | 444M | 394M | 400M | 505M | 457M | 422M | 498M | 482M | 567M |
| Cash & Short-term Investments | 166M | 173M | 349M | 268M | 213M | 222M | 241M | 50.3M | 143M | 123M | 195M |
| Total Debt | 5.31M | 4.48M | 158M | 165M | 168M | 170M | 174M | 1.84M | 2.20M | 4.26M | 4.33M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 26.4M | -10.0M | -10.2M | -18.8M | 13.0M | 12.6M | 33.2M | 22.7M | 162M | -11.6M | -29.5M |
| Capital Expenditure | 18.4M | 22.0M | 9.67M | 17.3M | 8.09M | 8.50M | 7.31M | 4.40M | 5.65M | 4.23M | 8.71M |
| Free Cash Flow | 7.98M | -32.0M | -19.8M | -36.2M | 4.90M | 4.11M | 25.9M | 18.3M | 157M | -15.8M | -38.2M |
| Ratios | |||||||||||
| ROE | 4.7% | -6.9% | -4.1% | -6.2% | -2.0% | 4.3% | 3.8% | -1.2% | 26.7% | -0.8% | -3.3% |
| ROA | 4.4% | -6.5% | -2.9% | -4.2% | -1.3% | 2.7% | 2.3% | -0.9% | 20.6% | -0.6% | -2.7% |
| Net Profit Margin | 28.6% | -48.3% | -27.5% | -39.2% | -13.0% | 33.3% | 16.9% | -5.3% | 49.9% | -3.5% | -9.5% |
| Debt to Equity | 0.01x | 0.01x | 0.36x | 0.42x | 0.42x | 0.34x | 0.38x | 0.00x | 0.00x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
COSMO N NV dividends
- Dividend yield
- 3.38%
- Forward dividend
- 1.92 CHF
- Payout ratio
- -
- Ex-dividend date
- Apr 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 32.9M | 2.06 | - |
| 2024 | EUR 32.1M | 1.95 | 24.1% |
| 2023 | EUR 16.9M | 1.05 | - |
| 2022 | EUR 15.6M | 0.95 | 90.6% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | 22.6M | 1.52 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns COSMO N NV
- Insiders 51.77%
- Institutions 17.09%
- Public & others 31.14%
- Shares outstanding 17.2M
- Free float 9.64M
COSMO N NV company profile
- Company name
- COSMO N NV
- Ticker
- CMHC.SW
- Exchange
- SIX Swiss Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 365
- Fiscal year end
- December
- Address
- Riverside 2, Dublin, Ireland, D02 KV60
- Phone
- 353 1 817 0370
- Website
- cosmohealthconfidence.com
About COSMO N NV
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. The company was founded in 1997 and is headquartered in Dublin, Ireland.
COSMO N NV management
10- Mr. Alessandro E. Della Cha LL.MNon Executive Chairman · born 1963
- Mr. Giovanni Di NapoliCEO & Director · born 1974
- Mr. Mauro Severino AjaniFounder & Non-Executive Director · born 1955
- Mr. Niall DonnellyExecutive VP of Corporate Governance, Chief Sustainability Officer & Executive Director · born 1972
- Ms. Svetlana SigalovaChief Financial Officer · born 1982
- Mr. Davide MalavasiSenior Vice President, Global Manufacturing, Qualified Person & Technical Director · born 1973
- Mr. Luigi LongoChief Scientific Officer · born 1979
- Mr. Federico SommarivaChief Legal Counsel · born 1985
- Ms. Silvia MilianiChief HR Officer · born 1971
- Mr. Ngo Dinh NhanPresident of Cosmo Intelligent Medical Devices · born 1979